As a consequence, therapeutic ablation of G2 checkpoints may preferentially make p53-deficient tumor cells sensitive to DNA damaging treatments while retaining normal cells with intact p53 function (Dixon and Norbury, 2002; Meng et al., 2018). The gene discussed is TP53; the disease is neoplasm.